(Q78785334)
Statements
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group (English)
Daniel Clarke-Pearson
Michael A Bookman
Kathleen M Darcy
Richard A Boothby